Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
It's certainly going to be an enormous source of problems going forwards, if it's anything like the common cold which has over 200 strains we are going to have many more Covid strains to look forward to, yikes!
Out of interest Mr ST where was the source you first found out about Covid back in Nov 2019?
Reckon you'll find the missing piece any day now
https://www.japantimes.co.jp/news/2021/04/14/national/japan-coronavirus-april14/
Just tried to sell all my shares and no problem at all, I clearly didn't as I fully grasp and understand this company and what it has in it's IP and how close the company is to launching the LFT. Who understands this company better than any of us here, Alastair Smith clearly does far more than any 'concerned' impatient investor on this board. Imagine the patience he has had since he started Avacta.
Some of you muppets aren't fit to wipe his a**e
"I’ve been in Avacta for over a year now and are happy for the gains but when you look at it there has been nothing good come out of any of the Partnerships or Collaborations. Not one deadline hit ever, no sales. No BAMS, no LFT" - TonyFawcett
That has to be the biggest single load of s**t spouted on this board in the time I have been reading and occasionally posting, and my god there's been some crap!
I suggest you take a look at the link below and maybe even purchase one and then think about the possibility that other scientists and labs maybe purchasing them as well.
https://adeptrix.com/store#!/SARS-CoV-2-S1-Glycoprotein/p/234586062/category=0
"So Avacta have provided a link to make it easier for people to obtain tests - which are tests from their competitors? You just couldn't make it up."
Hmmmmm interesting isn't it, it's almost like they might be getting ready to replace those tests
"They also get very emotional. I was always told to keep emotions out of business."
You seem emotional Sangijuelas1, if your worried then sell your shares and move on
"Then be corrected. 1) The NCYT drop was down to the announcement that their contract wouldn’t be renewed. 2) the government hasn’t bought 450,000 ion torrents from Nanopore. If Nanopore had sold 1% of that they’d be delighted."
Quite clearly the drop was because of the dropping of the contract but why was the question.
I did'nt say Ion Torrents you introduced that, I said machines/kits and the figure I stated was this from here:
"Separately, 450,000 90-minute LamPORE swab tests will also be available across adult care setting and laboratories from next week, supplied by Oxford Nanopore." - https://www.gov.uk/government/news/roll-out-of-2-new-rapid-coronavirus-tests-ahead-of-winter
I think NCYTs drop today is partly down to two companies, Oxford Nanopore mainly replacing a lot of PCR testing and then Avacta's roll out of LFT's, but I could be wrong. I know Nanopore machines have been starting to be used more in hospital settings (swab and saliva), I think the government bought 450,000 of their machines/kit, so I think it's a combination of the two but happy to be corrected. Nanopore machines will be able to do some of the genetics testing for Variants I would have thought.
I think will be one of the reasons for this loss of contract, the government bought 450,000 machines from Oxford Nanopore.
Sorry for the drop for genuine holders
And Avacta are involved in multiple hot areas
Antibody Mimetics, Diagnostic Reagents, Cancer Therapeutics, Antibody Drug Conjugates, and Covid Diagnostics
With the versatility of the Affimer platform, many further uses will no doubt be found as well
I like this bit:
"Avacta’s COVID-19 programmes are rapidly evolving"
"The belief that ADCs are the next big thing in cancer is a stance many in the industry are starting to adopt. Since the first ADC was approved in 2000, 10 of these enhanced antibodies have reached the market – seven of which have been approved since 2017. And activity in the space is booming. September last year saw Gilead acquire US ADC developer Immunomedics for $21 billion, while Merck paid $2.75 billion for ADC firm VelosBio in November, and in December, German firm Boehringer Ingelheim snapped up Swiss ADC company NBE-Therapeutics for €1.18 billion (£1 billion). Since 2012, more than 60 partnerships have been established, with around 60% of those deals taking place since 2015, pharma consultants Roots Analysis report."
"The promise of these next-generation drugs is substantial, and it goes beyond the realms of cancer. Research is already underway into ADCs to treat inflammatory conditions, as well as cardiovascular, metabolic and autoimmune diseases. There’s even interest in antibacterials, with antibody–antibiotic conjugates using a rifamycin analogue to treat Staphylococcus aureus already in development. The market is there for the taking. If companies aren’t interested in ADCs now, they soon will be."
So many potential uses for Affimers, the bit about Inflammatory and Autoimmune is exactly what the joint venture AffiXell with Daewoong is all about, HUUUUUGE markets!!
https://www.chemistryworld.com/news/antibody-drug-conjugates-drive-growth-in-oncology/4013371.article
That Independent article could have been written as the perfect reason why the Avacta LFT is really needed.
Welcome back PL75
Hi all, I bought in here this morning with a small amount, I like a few things about this company, the growing evidence of the benefits of cruciferous vegetables and the growing links to health effects and continuing evidence in Cell work with this compound. The link to Mr Jim Mellon who is a very astute cookie, also Ali Mortizavi (E-Therapeutics, Silence Therapeutics) who apparently holds c3,500,000 shares
Lets hope the Star Covid trials go well
Good luck all
Avacta and Cytiva (formerly GE Healthcare Life Sciences) collaborating on COVID-19 Rapid Test
COVID-19 Antigen Diagnostic Collaboration with Adeptrix
Avacta and Medusa19 Enter into a Distribution Agreement for COVID-19 Antigen Test
Collaboration with Integumen plc for Detection of SARS-COV-2 Coronavirus in Waste Water
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutralising Affimer Therapy
COVID-19 Rapid Antigen Test Manufacturing Partner - BBI Solutions
Avacta and LG Chem Life Sciences Expand Partnership
Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity - Abbingdon Health
Launch of SARS-CoV-2 BAMSTM Research Test
License Agreement with Astrea Bioseparations
Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin
License Agreement with POINT Biopharma Inc
Collaboration Agreement with Bruker
AffyXell $7.3 Million Series A Financing
Commercial Partnership with Mologic
Diagnostic Licensing Deal with Biokit
Distribution Agreement with ABCAM plc
It makes you wonder what on earth have they been doing all this time while we wait for the LFT!!! :)
Great post PSB123 and Darkspartan
Don't forget all the other companies as well especially Moderna
"since BAMS has been kicked into the long grass" -
Oh look it's RealityHunter with his false claims yet again, looks like your still full of lies :)
$1200
SARS-CoV-2 S1 Glycoprotein
Back to catalog
Product Details
The product is available to researchers involved in applying MALDI MS to viral typing. Contact us for additional details.
The kit contains high binding capacity magnetic beads conjugated to an Affimer® binder that recognizes an epitope within SARS-CoV-2 spike glycoprotein subunit 1 (S1 glycoprotein). The product is suitable for affinity precipitation and enrichment of native or recombinant SARS-CoV-2 spike glycoprotein. It may be also used for capturing intact virions containing the spike glycoprotein.
https://www.adeptrix.com/store#!/SARS-CoV-2-S1-Glycoprotein/p/234586062/category=0